What Are Growth Hormone Secretagogues? Complete Guide

After age 30, the amplitude of natural growth hormone pulses declines measurably, roughly 15% per decade, while pulse frequency stays relatively intact. For researchers studying the GH axis, that distinction matters. The question isn’t simply how to raise GH, but how to restore the signaling architecture that controls it. That’s where growth hormone secretagogues come in: a class of synthetic compounds that stimulate the pituitary to release GH endogenously, rather than bypassing the regulatory system entirely with exogenous hormone replacement.

Two structural families define this class. Peptide-based growth hormone releasing peptides (GHRPs) like ipamorelin, hexarelin, and GHRP-6 work through subcutaneous injection. Non-peptidic ghrelin mimetics like ibutamoren (MK-677) are small molecules engineered for oral bioavailability. Both families act on the same receptor system, GHS-R1a, the binding site targeted by ghrelin, the body’s own appetite and GH-regulating peptide. This guide covers the core receptor mechanism, structural taxonomy, compound-level comparisons, controlled research findings, and the regulatory and sourcing realities for lab procurement in 2026, providing the framework researchers need to make defensible protocol and procurement decisions.

How Growth Hormone Secretagogues Activate the GH Axis

GHS-R1a is a G protein-coupled receptor (GPCR) expressed in two critical locations: the hypothalamus (specifically the arcuate nucleus) and the somatotrope cells of the anterior pituitary. When a GHS compound binds this receptor, it activates Gαq/11 proteins, which trigger phospholipase C (PLC). PLC hydrolyzes PIP₂ into IP3 and DAG; IP3 then releases intracellular calcium from the endoplasmic reticulum, and that calcium surge drives GH exocytosis from somatotrope cells. Ghrelin is the endogenous ligand for this receptor, and every synthetic GHS compound, whether peptidic or not, exploits the same binding site. Reviews of ghrelin receptor signaling summarize these molecular steps and cellular locations in detail; see a representative review for further reading on ghrelin receptor signaling.

This pathway is distinct from the GHRH receptor pathway used by compounds like sermorelin and CJC-1295. Both pathways converge on pituitary GH release independently, which is why combining a GHS-R1a agonist with a GHRH receptor agonist produces synergistic GH output greater than either compound alone. In pre-clinical models, growth hormone secretagogues used alongside GHRH agonists consistently demonstrate this synergy, making it one of the most reproducible findings in the literature.

GHS compounds also suppress somatostatin tone in the hypothalamus, functioning as indirect somatostatin antagonists. Somatostatin is the primary inhibitory brake on GH secretion. By reducing that brake, growth hormone secretagogues potentiate GHRH-driven pulses and preserve the natural rhythmic, sleep-entrained pattern of GH release that exogenous GH therapy disrupts. The result is GH and IGF-1 restoration within physiological feedback loops, with IGF-1 providing negative regulation through somatostatin neurons that prevents the system from overshooting. This self-limiting feedback architecture is the core reason GHS research diverged from direct GH replacement as a scientific model.

The Two Main Families of GHS Compounds

GHRPs are short synthetic peptide chains, typically 6 to 8 amino acids, that act as GHS-R1a agonists and require subcutaneous injection to reach the pituitary. The three most studied representatives are GHRP-6 Acetate 5mg × 10 vials (the original hexapeptide), hexarelin peptide (the highest-potency GHRP), and ipamorelin (the most receptor-selective). All three share the same core mechanism but differ significantly in how narrowly they target GHS-R1a, and that selectivity difference shapes their side-effect profiles more than any other single factor. Oral bioavailability for GHRPs is negligible, roughly 0.3% for GHRP-6, which makes injection the only practical administration route in pre-clinical study designs.

Non-peptidic GHS compounds like ibutamoren (MK-677) were engineered specifically to overcome those pharmacokinetic constraints. MK-677 achieves approximately 60% oral bioavailability and a half-life of 4 to 6 hours, enabling reliable once-daily dosing. The tradeoff is a blunted peak: non-peptidic compounds raise mean 24-hour GH by 50 to 100% without the pronounced spike that characterizes injectable GHRPs. For chronic or longitudinal study designs where sustained GH/IGF-1 elevation matters more than pulse amplitude, that profile is often the better fit. Anamorelin and tabimorelin are two additional non-peptidic examples with clinical trial data in cachexia models, though MK-677 carries the most robust human evidence of the group.

Comparing Growth Hormone Secretagogues: Potency, Duration, and Selectivity

Potency

When choosing growth hormone secretagogues for acute versus chronic models, potency is the first differentiator. In pre-clinical rank-order studies, hexarelin produces the sharpest GH spikes, roughly 1.5 to 2 times more potent than GHRP-6 at equivalent molar doses, with ipamorelin producing peaks comparable to GHRP-6. Non-peptidic secretagogues like MK-677 raise mean 24-hour GH substantially but without the pronounced pulsatile spike that characterizes injectable GHRPs. Models requiring high-amplitude pulsatile GH output, such as muscle repair or acute signaling studies, consistently favor GHRPs on peak metrics.

Duration

Duration of effect separates the two families as clearly as potency. GHRPs carry half-lives of 15 to 30 minutes, and the resulting GH pulse resolves within 90 minutes, meaning chronic study designs require 2 to 3 injections per day to maintain effect. MK-677 reaches steady-state within days of daily oral dosing and maintains GH and IGF-1 elevation across the full 24-hour dosing window. Acute GH pulse models favor GHRPs; chronic or longitudinal GH axis studies favor oral non-peptidic compounds. That selection logic holds across most pre-clinical design decisions.

Selectivity

Receptor selectivity is where the three major GHRPs diverge most practically. Ipamorelin is GHS-R1a selective with minimal impact on cortisol, prolactin, or ACTH, making it the cleanest GHRP for isolated GH research. GHRP-6 and hexarelin activate non-GHS-R pathways, elevating cortisol and prolactin by 30 to 50% in research subjects, spillover that can confound results in any protocol where HPA axis stability matters. MK-677 avoids acute hormone spillover but introduces chronic metabolic effects with sustained use, including appetite stimulation, mild water retention, and a modest reduction in insulin sensitivity.

What Controlled Research Reveals About GHS Outcomes

The most rigorous human data on this compound class comes from a 2-year double-blind, randomized, placebo-controlled trial of MK-677 at 25 mg daily in healthy adults aged 60 to 81. Over 12 months, 24-hour mean GH increased 1.8-fold, IGF-1 rose to young-adult ranges, and fat-free mass increased by 1.1 kg in the MK-677 arm versus a 0.5 kg loss in placebo recipients. Bone mineral density trended positive, consistent with enhanced bone remodeling signals at the 12-month mark. These effects were sustained through the second year in continuers and reversed upon crossover to placebo; the trial is registered as NCT00474279 with publicly available methodology and outcome measures.

The findings are meaningful but come with important boundaries. No significant reduction in fat mass was observed, and neither functional strength nor quality-of-life measures improved despite the clear body composition changes. That result indicates that GH and IGF-1 elevation alone does not translate directly to functional endpoints in older cohorts, a critical distinction for researchers designing outcome models. Body composition changes and functional performance are not the same endpoint, and GHS studies that treat them interchangeably are drawing conclusions the data do not support.

Safety signals from controlled GHS research are consistent across compounds. The most common findings in the MK-677 RCT were increased appetite in 67% of recipients, a modest cortisol elevation, and an HbA1c increase of approximately 0.2% with sustained dosing. That glycemic shift did not reach clinical significance in most participants but warrants monitoring in metabolically vulnerable populations. In the Alzheimer’s disease trial, hyperglycemia was reported in 15.4% of MK-677 recipients versus 4.6% on placebo, a gap worth noting for any researcher designing protocols involving diabetic or pre-diabetic models. Systematic reviews and clinical summaries of ghrelin receptor agonists discuss these chronic metabolic signals and monitoring recommendations in more detail; see a clinical review for context on ghrelin agonist safety and metabolic effects. Ipamorelin’s selective receptor profile avoids cortisol and prolactin elevation entirely, which is why it remains the preferred injectable GHRP in protocols where clean GH isolation is the research objective.

Regulatory Status and Sourcing Growth Hormone Secretagogues Responsibly

In the US, all four major GHS compounds, ibutamoren, GHRP-6, hexarelin, and ipamorelin, are unapproved investigational new drugs under FDA regulation. They are explicitly excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the FD&C Act. None are DEA controlled substances, and purchasing them for laboratory and research purposes is legal. Marketing or selling them for human consumption triggers FDA enforcement, which has included warning letters to supplement companies and, more recently, state-level pharmacy board actions against compounding operations distributing these compounds for clinical use without authorization.

The regulatory picture in the EU is stricter. No marketing authorization exists for any of these compounds as supplements, and they are treated as unapproved pharmaceuticals requiring specific authorization for distribution. Ibutamoren is the furthest along in the clinical development pipeline: Lumos Pharma has it in Phase 3 trials for growth hormone deficiency as of 2026, but no commercial approval has been granted. Ipamorelin was removed from FDA Category 2 status following the October 2024 PCAC review and is awaiting the July 2026 committee meeting to determine Category 1 eligibility, which would still require physician supervision and licensed pharmacy compounding rather than open commercial sale.

For labs procuring growth hormone secretagogues for pre-clinical work, lot-traceable Certificates of Analysis (COAs) with HPLC purity data are non-negotiable. They establish compound identity, confirm purity percentage, and provide the documentation trail that internal quality standards and research integrity require. Sourcing multiple GHS compounds from a single verified supplier simplifies procurement workflows considerably for multi-compound study designs. R-Peptide Supply (Grey Peptide Shop) carries several key GHS peptides, including ipamorelin, hexarelin, and GHRP-6 variants, in bulk and multi-vial formats, each backed by verified COA documentation. For labs needing documented quality across multiple compounds without splitting orders across vendors, that single-source model reduces friction and keeps procurement auditable, for additional supplier resources and procurement guidance see the Blog, Research Peptides Supply.

Putting the Pieces Together for Research Design

Growth hormone secretagogues are mechanistically distinct from direct GH replacement. They work through GHS-R1a and the ghrelin pathway to restore pulsatile GH secretion within the body’s feedback architecture, not around it. That distinction shapes both the research utility of these compounds and the safety profile that controlled trials have documented. Understanding it is prerequisite to designing protocols that generate interpretable data rather than confounded endpoints.

The peptide-versus-non-peptidic split is the first selection decision any researcher faces. Within GHRPs, ipamorelin’s selectivity, hexarelin’s potency, and GHRP-6’s established pharmacokinetic baseline each serve different protocol objectives. None of these growth hormone secretagogues are interchangeable, and treating them as equivalent options produces inconsistent results and confounded endpoints.

All GHS compounds remain research-use-only in the US and EU. Compliance framing and COA documentation are not optional for lab procurement, they are the foundation of defensible research practice. For labs building multi-compound GHS protocols and needing a wholesale source with verified purity documentation, R-Peptide Supply (Grey Peptide Shop) offers catalog depth and COA infrastructure to support that work without the overhead of managing multiple vendors. Confirm compound specifications against your protocol requirements, verify the COA against your lot number, and build your study on documented inputs.